Plasma Proteome-Based Test for First-line Treatment Selection in Metastatic Non–Small Cell Lung Cancer

In the tumor microenvironment (Tumor Microenvironment, TME), Immune Checkpoint Inhibitors (ICIs) targeting PD-1 or PD-L1 enhance the body’s natural ability to eliminate cancer cells by disrupting the inhibitory receptor-ligand interaction. However, even so, critical trials indicate that the response rate for monotherapy is <50%, with a median Progr...

Prognostic Model for High-Grade Neuroendocrine Carcinoma of the Lung Incorporating Genomic Profiling and Poly (ADP-Ribose) Polymerase-1 Expression

Prognostic Model for High-Grade Neuroendocrine Carcinoma of the Lung Incorporating Genomic Profiling and Poly (ADP-Ribose) Polymerase-1 Expression

Prognostic Model of Pulmonary High-grade Neuroendocrine Carcinoma: Integrating Genomic Analysis and Poly(ADP-ribose) Polymerase-1 Expression Research Background High-grade neuroendocrine carcinoma (HGNEC) of the lung is a highly aggressive cancer with significant biological complexity. Despite its association with Notch pathway activation and inact...

High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer

High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer

Ovarian cancer is one of the most common and deadly tumor types in women. In recent years, Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown encouraging clinical results in the treatment of ovarian cancer. Numerous studies have found that patients with homologous recombination deficiency (HRD) benefit more from PARPi treatment. Therefore, ...

Prognostic Value of Serial Postoperative Circulating Tumor DNA Assessment During Long-Term Follow-Up in Patients with Breast Cancer

Prognostic Value of Serial Postoperative Circulating Tumor DNA Assessment During Long-Term Follow-Up in Patients with Breast Cancer

Scientific Research Report Background Introduction Breast cancer is the most commonly diagnosed cancer worldwide among both men and women, and it is the leading cause of cancer-related deaths in women. The standard treatment for early-stage breast cancer usually involves surgery and (neo)adjuvant chemotherapy and/or endocrine therapy, aiming to eli...

Clinical Validation of AI-Powered PD-L1 Tumor Proportion Score Interpretation for Predicting Immune Checkpoint Inhibitor Response in NSCLC

Clinical Validation of AI-based Interpretation of PD-L1 Tumor Proportion Score in Predicting Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer In the field of tumor treatment and diagnosis, the assessment of PD-L1 (Programmed Death-Ligand 1) Tumor Proportion Score (TPS) is a critical task, especially in predicting the response ...

Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients with Newly Diagnosed Prostate Cancer

Using Cell Cycle Risk Score to Predict the Benefit of Radiotherapy Combined with ADT in Newly Diagnosed Prostate Cancer Patients Background Prostate cancer is one of the most common cancers among men globally. In terms of treatment, localized prostate cancer is often treated primarily with radiotherapy (RT). However, the efficacy of RT alone is oft...

Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients with Advanced Prostate Cancer from Latin America: Challenges and Future Approaches

Academic Report for the Paper Titled “Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients with Advanced Prostate Cancer from Latin America: Challenges and Future Approaches” Background Prostate cancer is one of the most common cancers among men in Latin America and the Caribbean (LAC). According to the 2020 Glo...

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients

Precision Medicine | Quantitative Comprehensive Survival Prediction for Patients with Multiple Myeloma: Based on Bortezomib Induction Therapy, High-Dose Treatment, and Autologous Stem Cell Transplantation Introduction Multiple myeloma is a malignant hematological disease characterized by the accumulation of clonal plasma cells within the bone marro...

Clonal Hematopoiesis in Patients with Neuroendocrine Tumor Treated with Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study

Clonal Hematopoiesis in Patients with Neuroendocrine Tumor Treated with Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study

Clonal Hematopoiesis and Risk of Thrombocytopenia in Neuroendocrine Tumor Patients Undergoing 177Lu Therapy: A Prospective Study Background and Research Motivation The incidence of Neuroendocrine Tumors (NETs) has gradually increased in recent years. Prognosis depends on various factors such as the location of the primary tumor, disease grading, st...

Association of Timely Comprehensive Genomic Profiling with Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer

Association of Timely Comprehensive Genomic Profiling with Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer

Study on the Association Between the Timeliness of Comprehensive Genomic Profiling in Precision Oncology and Treatment Choices and Outcomes for Patients with Advanced Non-Small Cell Lung Cancer Introduction Advanced non-small-cell lung cancer (ANSCLC) is a highly lethal malignancy, and treatment choices directly affect the overall survival rate of ...